Casi Pharmaceuticals (CASI)

[Rocky I]

CASI Pharmaceuticals Announces Poster Presentations At AACR Annual Meeting
ROCKVILLE, Md., March 28, 2017 - CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs, announced today two poster presentations at the American Association for Cancer Research annual meeting. The first poster to be presented on April 3 is entitled “Evaluation of ENMD-2076 in Combination with Anti-PD1 in Syngeneic Cancer Models” and the second poster to be presented on April 4 is entitled “Kinase Inhibitor Demonstrates Efficacy in Patient Derived Xenograft Model of Fibrolamellar Hepatocellular Carcinoma Featuring DNAJB1-PRKACA Gene Fusion.”

Session Category: Immunology
Session Title: Tumor Microenvironment and Checkpoints
Session Date and Time: Monday Apr 3, 2017, 8:00 AM - 12:00 PM ET
Location: Convention Center, Halls A-C, Poster Section 27
Poster Board Number: 20
Permanent Abstract Number: 1642

Session Category: Experimental and Molecular Therapeutics
Session Title: Targeting Protein Kinases and DNA Repair
Session Date and Time: Tuesday Apr 4, 2017 1:00 PM - 5:00 PM ET
Location: Convention Center, Halls A-C, Poster Section 7
Poster Board Number: 26
Permanent Abstract Number: 4203